drugset / Trial / NCT04429867

Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease

NCT04429867

Phase 4 Unknown 700 enrolled WellStar Health System
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective is to assess the impact of hydroxychloroquine in hospitalized patients with COVID-19 and risk factors for severe/critical disease.

Timeline

Start
2020-05-07
Primary completion
2020-12-07
Completion
2020-12-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 200 mg Oral

Indications